[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021012769A - Anticuerpos bloqueadores cd73. - Google Patents

Anticuerpos bloqueadores cd73.

Info

Publication number
MX2021012769A
MX2021012769A MX2021012769A MX2021012769A MX2021012769A MX 2021012769 A MX2021012769 A MX 2021012769A MX 2021012769 A MX2021012769 A MX 2021012769A MX 2021012769 A MX2021012769 A MX 2021012769A MX 2021012769 A MX2021012769 A MX 2021012769A
Authority
MX
Mexico
Prior art keywords
compounds
blocking antibodies
antibodies
fragments
methods
Prior art date
Application number
MX2021012769A
Other languages
English (en)
Inventor
Laurent Gauthier
Ivan Perrot
Carine Paturel
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of MX2021012769A publication Critical patent/MX2021012769A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de los mismos que se unen e inhiben CD73. La invención también se refiere a células que producen tales compuestos; procedimientos para preparar dichos compuestos y anticuerpos, fragmentos, variantes y derivados de los mismos; composiciones farmacéuticas que lo comprenden; procedimientos de uso de los compuestos para diagnosticar, tratar o prevenir enfermedades, por ejemplo, cáncer.
MX2021012769A 2019-04-23 2020-04-20 Anticuerpos bloqueadores cd73. MX2021012769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837214P 2019-04-23 2019-04-23
PCT/EP2020/060955 WO2020216697A1 (en) 2019-04-23 2020-04-20 Cd73 blocking antibodies

Publications (1)

Publication Number Publication Date
MX2021012769A true MX2021012769A (es) 2021-11-18

Family

ID=70456747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012769A MX2021012769A (es) 2019-04-23 2020-04-20 Anticuerpos bloqueadores cd73.

Country Status (13)

Country Link
US (1) US20220041744A1 (es)
EP (1) EP3959239A1 (es)
JP (1) JP7530913B2 (es)
KR (1) KR20220002959A (es)
CN (1) CN113784981A (es)
AU (1) AU2020260693A1 (es)
BR (1) BR112021021224A2 (es)
CA (1) CA3136698A1 (es)
IL (1) IL286997A (es)
MX (1) MX2021012769A (es)
SG (1) SG11202111106WA (es)
TW (1) TWI834867B (es)
WO (1) WO2020216697A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
EP3692068B1 (en) * 2017-10-06 2022-12-07 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
EP4084870A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
WO2021138467A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Anti-cd73 antibodies and uses thereof
US20240270865A1 (en) * 2020-08-13 2024-08-15 Innate Pharma Cancer treatment methods using anti-cd73 antibodies
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7351803B2 (en) 2002-05-30 2008-04-01 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
WO2006121168A1 (en) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
CA2992770A1 (en) 2009-11-24 2011-06-03 Medimmune Limited Targeted binding agents against b7-h1
RS55460B1 (sr) 2009-11-30 2017-04-28 Janssen Biotech Inc Mutirana fc antitela sa uklonjenom efektorskom funkcijom
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
KR20230125855A (ko) * 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
EP3362475B1 (en) 2015-10-12 2023-08-30 Innate Pharma Cd73 blocking agents
KR20180134837A (ko) 2015-12-09 2018-12-19 코버스 파마슈티칼스, 인크. 인간화된 항-cd73 항체
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
WO2019243252A1 (en) * 2018-06-18 2019-12-26 Innate Pharma Compositions and methods for treating cancer

Also Published As

Publication number Publication date
TW202104268A (zh) 2021-02-01
CA3136698A1 (en) 2020-10-29
IL286997A (en) 2021-12-01
EP3959239A1 (en) 2022-03-02
TWI834867B (zh) 2024-03-11
US20220041744A1 (en) 2022-02-10
BR112021021224A2 (pt) 2021-12-21
KR20220002959A (ko) 2022-01-07
JP7530913B2 (ja) 2024-08-08
WO2020216697A1 (en) 2020-10-29
JP2022530404A (ja) 2022-06-29
CN113784981A (zh) 2021-12-10
AU2020260693A1 (en) 2021-10-28
SG11202111106WA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
MX2021012769A (es) Anticuerpos bloqueadores cd73.
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2023002507A (es) Inhibidores de cd73.
MY200162A (en) Anti-gitr antibodies and uses thereof
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
ZA202202363B (en) Antibodies against ilt2 and use thereof
MX2020012107A (es) Composiciones y procedimientos para el tratamiento del cancer.
WO2015054600A3 (en) Glycan-interacting compounds and methods of use
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
MX2022005256A (es) Inhibidores de cd73.
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
EA202092121A1 (ru) Антитела против cd73 и их применения